UK approves Pharming's Joenja for children aged 4-11 with APDS weighing at least 27 kg
PHAR•The U.K. MHRA approved Joenja for children aged 4 to 11 with APDS who weigh at least 27 kg, with doses of 40 mg or 50 mg twice daily. The treatment is expected to become available to newly eligible patients in February 2027.
1. Expanded authorization
The U.K. MHRA expanded Pharming's Joenja (leniolisib) authorization to children aged 4 to 11 with APDS who weigh at least 27 kg. The authorized dose is 40 mg or 50 mg twice daily, and the treatment is expected to become available to newly eligible patients in February 2027. The expanded indication extends access beyond adults and adolescents aged 12 or older.
